Join BJS Academy
BJS Academy>Randomized clinical ...>Effect of metformin ...
Normal View Dyslexic View

Effect of metformin vs placebo on invasive disease–free survival in patients with breast cancer. The MA.32 randomized clinical trial.

13 July 2022
Randomized clinical trials Breast
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J et al.

JAMA 2022; 327: 1963-1973.

This study included 3643 non diabetic women, who were followed for a median of 96.2 months. Metformin did not have any advantage for women with ER positive (hazard ratio for invasive disease-free survival 1.01, 95 per cent confidence interval 0.84 to 1.21, P=0.93) or ER negative breast cancer (1.01, 0.79 to 1.3, P=0.92).

Comment: Science is the destruction of a beautiful idea by an ugly fact.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct211
Randomized clinical trials
Randomized clinical trials
Breast
Effect of metformin vs placebo on invasive disease–free survival in patients with breast cancer. The MA.32 randomized clinical trial.
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J et al.
13072022
JAMA 2022; 327: 1963-1973.
This study included 3643 non diabetic women, who were followed for a median of 96.2 months. Metformin did not have any advantage for women with ER positive (hazard ratio for invasive disease-free survival 1.01, 95 per cent confidence interval 0.84 to 1.21, P=0.93) or ER negative breast cancer (1.01, 0.79 to 1.3, P=0.92).
Comment: Science is the destruction of a beautiful idea by an ugly fact.
Published on: 13 July 2022
Article ID: rct211

Related articles

Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.

Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.

16 August 2024

21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF et al.
N Engl J Med 2021; 385: 2336-2347

1 January 2022

Event-free survival with pembrolizumab in early triple-negative breast cancer.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S et al, for the KEYNOTE-522 Investigators.
N Engl J Med 2022; 386: 556-567.

1 March 2022
Home
  • Normal view
  • Dyslexic view
Info
Copied!